|
CNBC'S MOST SHARED
- A Goldman Trading Scandal?
- The Threat of Ballooning Pensions
- SEC May Reinstate Rules for Short-Selling Stocks
- Malaysia PM Speaks to CNBC
- Your First Move For Monday July 6th
- The Rising Mountain of Debt May Be the Next Crisis
- Texting And Driving Worse Than Drinking and Driving
- Hey, What's Up Doc?
- Rich People With A Death Wish
- Ex-Goldman Programmer Must Post $750,000 Bail
- Farrell: Don't Head For The Exits Yet
- Justice Dept Said to Be Looking At Telecom Giants
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- US Service Sector Has Best Showing In Months
- GM A Step Closer To Exiting Bankruptcy
- Tribune, Cubs Deal Agreed In Principle
- Facebook Director Sees 'Billions' in Revenue in 5 Years
- Judge Gives Control of Jackson Estate to Executors
- Hey, What's Up Doc?
- Busch: Summertime Blues Hits Investors
- Chadwick: Recession and Scandals Pave the Way for Romney 2012
- Art Cashin: The S&P's 'Head and Shoulders' Number
- Michael Jackson: Death And Taxes
- Is Andy’s Mojo Back? We Asked Him
- GM A Step Closer To Exiting Bankruptcy
- Schork Oil Outlook: The Fear Trade
- Market's Monday Blues
Text Size 
NEW YORK - Eli Lilly has downplayed for about 10 years the risks associated with Zyprexa, which treats schizophrenia, The New York Times said on its Web site Sunday, citing internal documents from the drug maker and e-mail messages of its managers.
The documents, obtained from a lawyer for mentally ill patients, show Lilly [LLY
Loading...
()
] executives kept data from doctors about the drug's tendencies to promote obesity and boost blood sugar, the newspaper said.
Zyprexa is Lilly's best-selling product. With sales of $4.2 billion last year, about 2 million people worldwide were taking the drug.
Thirty percent of patients taking Zyprexa gain 22 pounds or more after a year on the drug, and some patients have reported putting on more than 100 pounds, according to information published by Lilly. But the internal documents, which cover the period from 1995 to 2004, show Lilly feared sales would be hurt if the company was open with doctors the drug's side effects, the paper said.
Lilly denied there was a connection between the drug and diabetes on Friday in a written response to questions about the documents, according to The New York Times. The drug maker said the documents had been taken out of context, the newspaper said.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes